Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Target Price at $12.50

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $12.50.

Several research firms have recently weighed in on ALXO. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. UBS Group reduced their price objective on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 16th. Stifel Nicolaus reissued a “hold” rating and set a $3.00 price target (down from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th.

Insider Activity at ALX Oncology

In other ALX Oncology news, Director Rekha Hemrajani acquired 30,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was bought at an average cost of $1.55 per share, with a total value of $46,500.00. Following the completion of the transaction, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. This represents a 1,000.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 33.40% of the company’s stock.

Institutional Trading of ALX Oncology

A number of hedge funds have recently made changes to their positions in the business. CANADA LIFE ASSURANCE Co acquired a new stake in shares of ALX Oncology in the first quarter valued at approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after buying an additional 5,200 shares during the last quarter. Rhumbline Advisers lifted its position in shares of ALX Oncology by 10.8% in the second quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock valued at $333,000 after buying an additional 5,360 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after buying an additional 6,080 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after buying an additional 6,888 shares during the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Stock Up 0.6 %

ALXO stock opened at $1.56 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The stock has a market capitalization of $82.27 million, a P/E ratio of -0.52 and a beta of 1.04. The business has a 50-day moving average of $1.52 and a 200-day moving average of $4.17. ALX Oncology has a fifty-two week low of $1.19 and a fifty-two week high of $17.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.